Literature DB >> 20574774

Morbidity of sentinel node biopsy in breast cancer: the relationship between the number of excised lymph nodes and lymphedema.

Jessica I Goldberg1, Lisa I Wiechmann, Elyn R Riedel, Monica Morrow, Kimberly J Van Zee.   

Abstract

BACKGROUND: Despite the reduced morbidity associated with sentinel lymph node biopsy (SLNB), lymphedema remains a clinically relevant complication. We hypothesized that a higher number of lymph nodes (LNs) removed during SLNB is associated with a higher risk of lymphedema.
METHODS: Six hundred patients with clinically node-negative breast cancer who underwent SLNB were prospectively studied. Circumferential bilateral upper extremity measurements were performed preoperatively and at 3-8 years after surgery. Association of lymphedema with total number of LNs excised and other clinicopathologic variables was analyzed by the Spearman rank correlation coefficient, Fisher's exact test, Wilcoxon rank sum test, and logistic regression.
RESULTS: At a median follow-up of 5 years, 5% of patients had developed lymphedema. Factors associated with lymphedema included weight and body mass index. There was no association between the number of LNs removed and the change in upper extremity measurements or in the incidence of lymphedema. Among patients with lymphedema (n = 31) compared to those without, the mean (3.9 vs. 4.2), median (4 vs. 3), and range (1-9 vs. 1-17) of number of LNs removed were similar (P = 0.93). Among the 33 women with ≥ 10 LNs removed, none developed lymphedema.
CONCLUSIONS: In this population of 600 women who underwent SLNB, there is no correlation between number of LNs removed and change in upper extremity circumference or incidence of lymphedema. These data suggest that other factors, such as the global disruption of the lymphatic channels during axillary lymph node dissection, play a larger role in development of lymphedema than does the number of LNs removed.

Entities:  

Mesh:

Year:  2010        PMID: 20574774     DOI: 10.1245/s10434-010-1155-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  20 in total

1.  Impact of body mass index and weight fluctuation on lymphedema risk in patients treated for breast cancer.

Authors:  Lauren S Jammallo; Cynthia L Miller; Marybeth Singer; Nora K Horick; Melissa N Skolny; Michelle C Specht; Jean O'Toole; Alphonse G Taghian
Journal:  Breast Cancer Res Treat       Date:  2013-11       Impact factor: 4.872

Review 2.  Accuracy of axillary ultrasound in the diagnosis of nodal metastasis in invasive breast cancer: a review.

Authors:  Jonathan Cools-Lartigue; Sarkis Meterissian
Journal:  World J Surg       Date:  2012-01       Impact factor: 3.352

3.  Acupuncture for breast cancer-related lymphedema: a randomized controlled trial.

Authors:  Ting Bao; Wanqing Iris Zhi; Emily A Vertosick; Qing Susan Li; Janice DeRito; Andrew Vickers; Barrie R Cassileth; Jun J Mao; Kimberly J Van Zee
Journal:  Breast Cancer Res Treat       Date:  2018-03-08       Impact factor: 4.872

4.  Comparison of relative versus absolute arm size change as criteria for quantifying breast cancer-related lymphedema: the flaws in current studies and need for universal methodology.

Authors:  Marek Ancukiewicz; Cynthia L Miller; Melissa N Skolny; Jean O'Toole; Laura E Warren; Lauren S Jammallo; Michelle C Specht; Alphonse G Taghian
Journal:  Breast Cancer Res Treat       Date:  2012-06-19       Impact factor: 4.872

Review 5.  Recent progress in the treatment and prevention of cancer-related lymphedema.

Authors:  Simona F Shaitelman; Kate D Cromwell; John C Rasmussen; Nicole L Stout; Jane M Armer; Bonnie B Lasinski; Janice N Cormier
Journal:  CA Cancer J Clin       Date:  2014-11-19       Impact factor: 508.702

6.  Immediate Implant Reconstruction Is Associated With a Reduced Risk of Lymphedema Compared to Mastectomy Alone: A Prospective Cohort Study.

Authors:  Cynthia L Miller; Amy S Colwell; Nora Horick; Melissa N Skolny; Lauren S Jammallo; Jean A O'Toole; Mina N Shenouda; Betro T Sadek; Meyha N Swaroop; Chantal M Ferguson; Barbara L Smith; Michelle C Specht; Alphonse G Taghian
Journal:  Ann Surg       Date:  2016-02       Impact factor: 12.969

7.  Risk factors associated with breast cancer-related lymphedema in the WHEL Study.

Authors:  Sally A Dominick; Lisa Madlensky; Loki Natarajan; John P Pierce
Journal:  J Cancer Surviv       Date:  2012-12-05       Impact factor: 4.442

Review 8.  Lymphedema following treatment for breast cancer: a new approach to an old problem.

Authors:  Jean O'Toole; Lauren S Jammallo; Melissa N Skolny; Cynthia L Miller; Krista Elliott; Michelle C Specht; Alphonse G Taghian
Journal:  Crit Rev Oncol Hematol       Date:  2013-06-16       Impact factor: 6.312

9.  Defining a threshold for intervention in breast cancer-related lymphedema: what level of arm volume increase predicts progression?

Authors:  Michelle C Specht; Cynthia L Miller; Tara A Russell; Nora Horick; Melissa N Skolny; Jean A O'Toole; Lauren S Jammallo; Andrzej Niemierko; Betro T Sadek; Mina N Shenouda; Dianne M Finkelstein; Barbara L Smith; Alphonse G Taghian
Journal:  Breast Cancer Res Treat       Date:  2013-08-04       Impact factor: 4.872

Review 10.  Cost-effectiveness analyses demonstrate that observation is superior to sentinel lymph node biopsy for postmenopausal women with HR + breast cancer and negative axillary ultrasound.

Authors:  Aubriana M McEvoy; Steven Poplack; Katelin Nickel; Margaret A Olsen; Foluso Ademuyiwa; Imran Zoberi; Elizabeth Odom; Jennifer Yu; Su-Hsin Chang; William E Gillanders
Journal:  Breast Cancer Res Treat       Date:  2020-07-10       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.